Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

RGNX

Regenxbio Inc

May 22 • 04:00PM ET

6.35

-0.40 -5.93 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: NGNE FDMT QURE STOK EDIT

| Held by: VTI XBI IWM VXF IWN IBB VTWO FESM KOMP SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.59	Insider Own	9.34%	Shs Outstand	51.62M	Perf Week	11.01%
Market Cap	328.28M	Forward P/E	-	EPS next Y	-2.92	Insider Trans	-0.42%	Shs Float	46.87M	Perf Month	-29.37%
Enterprise Value	426.19M	PEG	-	EPS next Q	0.25	Inst Own	81.16%	Short Float	14.28%	Perf Quarter	-20.03%
Income	-290.01M	P/S	3.74	EPS this Y	24.27%	Inst Trans	3.47%	Short Ratio	5.89	Perf Half Y	-41.90%
Sales	87.82M	P/B	15.55	EPS next Y	-2.52%	ROA	-69.65%	Short Interest	6.69M	Perf YTD	-55.90%
Book/sh	0.41	P/C	2.18	EPS next 5Y	28.01%	ROE	-196.43%	52W High	16.19 -60.78%	Perf Year	-35.60%
Cash/sh	2.91	P/FCF	-	EPS past 3/5Y	16.67% -4.73%	ROIC	-117.23%	52W Low	5.45 16.41%	Perf 3Y	-69.07%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	14.78% 1.97%	Gross Margin	50.52%	Volatility	9.14% 9.11%	Perf 5Y	-81.92%
Dividend TTM	-	EV/Sales	4.85	EPS Y/Y TTM	-78.31%	Oper. Margin	-292.28%	ATR (14)	0.77	Perf 10Y	-47.30%
Dividend Ex-Date	-	Quick Ratio	2.62	Sales Y/Y TTM	-43.96%	Profit Margin	-330.23%	RSI (14)	35.97	Recom	1.42
Dividend Gr. 3/5Y	- -	Current Ratio	2.62	EPS Q/Q	-1551.90%	SMA20	-23.63%	Beta	1.07	Target Price	25.92
Payout	-	Debt/Eq	11.78	Sales Q/Q	-92.82%	SMA50	-25.66%	Rel Volume	1.38	Prev Close	6.75
Employees	371	LT Debt/Eq	10.74	Earnings	May 14 BMO	SMA200	-39.54%	Avg Volume	1.14M	Price	6.35
IPO	Sep 17, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-28.65% -75.26%	Trades		Volume	1,569,482	Change	-5.93%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Overweight	$37
Feb-11-25	Downgrade	Goldman	Buy → Neutral	$38 → $14
Feb-07-25	Resumed	Raymond James	Outperform	$27
Nov-15-24	Resumed	Morgan Stanley	Overweight	$22
Oct-10-24	Resumed	Raymond James	Outperform	$18
Jun-07-24	Initiated	Goldman	Buy	$38
Mar-11-24	Initiated	H.C. Wainwright	Buy	$36
Mar-08-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$20 → $35
Mar-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$37
Feb-21-24	Resumed	Raymond James	Outperform	$45
Nov-01-23	Initiated	Stifel	Buy	$35
Jun-02-23	Initiated	Robert W. Baird	Outperform	$42
Jun-23-22	Initiated	Berenberg	Buy	$61
Dec-15-21	Initiated	Wedbush	Neutral	$29
Oct-19-21	Resumed	Morgan Stanley	Overweight	$62 → $50
Jan-06-21	Upgrade	Raymond James	Outperform → Strong Buy	$60
Dec-16-20	Initiated	UBS	Buy	$57
Jun-25-20	Resumed	BofA/Merrill	Buy	$9
Jun-25-20	Resumed	BofA/Merrill	Buy	$60
May-13-20	Initiated	RBC Capital Mkts	Sector Perform	$42

Show Previous Ratings

May-18-26 04:05PM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
May-14-26 07:03PM	Regenxbio Inc (RGNX) Q1 2026 Earnings Call Highlights: Promising RGX-202 Results and Path to ... (GuruFocus.com) -37.80% -8.41%
10:09AM	Regenxbio Shares Rise After Positive Duchenne Trial Results (InvestorsHub)
07:18AM	Regenxbio: Q1 Earnings Snapshot (Associated Press)
07:10AM	REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights (PR Newswire)
07:00AM	Loading…
07:00AM	REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE Study of RGX-202 (PR Newswire)
05:10AM	With new data, Regenxbio to seek FDA approval of Duchenne gene therapy (BioPharma Dive)
May-07-26 07:05AM	REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting (PR Newswire)
May-06-26 07:05AM	REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy (PR Newswire) +10.85%
Apr-01-26 09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP (PR Newswire)
Mar-30-26 04:06AM	REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX (PR Newswire)
Mar-26-26 09:00AM	SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD (PR Newswire)
Mar-25-26 02:11PM	Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval (Investor's Business Daily) +8.32%
05:01AM	Mixed signals cloud the orphan drug market (Pharma Voice)
Mar-24-26 04:00PM	RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP (Business Wire) -6.35%
09:00AM	Loading…
Mar-19-26 09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP (PR Newswire)
Mar-17-26 04:00PM	Stephen Pakola Oversaw RGX-111 Safety Claims That Cost RGNX Investors Millions: Levi & Korsinsky, LLP (Business Wire)
Mar-12-26 09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST (PR Newswire)
Mar-11-26 11:45AM	REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE TRIAL OF RGX-202 (PR Newswire) -5.25%
09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP (PR Newswire)
Mar-10-26 04:00PM	RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP (Business Wire)
Mar-09-26 04:37PM	This biotech's stock soared after a 'polarizing' FDA official is stepping down (MarketWatch) +20.00%
01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga)
01:15PM	Biotech Stocks Rally on Departure of Polarizing FDA Official (The Wall Street Journal)
08:23AM	uniQure stock surges 36% on FDA officials departure (Investing.com)
Mar-06-26 05:56PM	FDA vaccine chief Vinay Prasad set to leave post next month (Bloomberg)
12:10AM	REGENXBIO Q4 Earnings Call Highlights (MarketBeat)
Mar-05-26 02:25PM	RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST (PR Newswire)
02:02PM	Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience (GuruFocus.com)
08:30AM	REGENXBIO Inc. Q4 2025 Earnings Call Summary (Moby)
08:25AM	Loading…
08:25AM	Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:23AM	Regenxbio: Q4 Earnings Snapshot (Associated Press Finance)
07:05AM	REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights (PR Newswire)
Mar-04-26 09:00AM	REGENXBIO Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RGNX (PR Newswire) +5.18%
07:05AM	REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire)
Mar-03-26 05:30AM	MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines (The Wall Street Journal) -5.95%
Mar-02-26 05:58PM	REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses (PR Newswire)
10:00AM	Adherex Technologies Inc. (FENC) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-27-26 12:49AM	QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? (New feeds test provider finance)
Feb-26-26 04:06PM	Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug (Investor's Business Daily)
10:00AM	Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-25-26 07:05AM	REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights (PR Newswire) +5.57%
Feb-20-26 04:19AM	REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX (PR Newswire)
Feb-17-26 07:30AM	REGENXBIO Inc. Sued for Securities Law Violations Contact the DJS Law Group to Discuss Your Rights RGNX (Business Wire)
Feb-10-26 08:51AM	FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment (Benzinga) -14.16%
06:19AM	FDA rejects Regenxbio treatment in another blow to gene therapy (BioPharma Dive)
05:49AM	REGENXBIO receives FDA response for RGX-121 application (Pharmaceutical Business Review)
Feb-09-26 04:05PM	REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II (PR Newswire)
Feb-02-26 12:18AM	Lost Money on REGENXBIO Inc. (RGNX)? Possible Fraud - Contact Levi & Korsinsky Today (Newsfile)
Jan-30-26 06:40AM	Regenxbio (RGNX) Soars 5.4%: Is Further Upside Left in the Stock? (Zacks)
Jan-29-26 10:10AM	Regenxbio selloff an overreaction to clinical hold, says Leerink (TipRanks) +5.36%
Jan-28-26 12:31PM	FDA Clinical Hold Knocks REGENXBIO Stock (Benzinga) -17.90%
09:22AM	The 'Confusing And Unexpected' Update That Slammed Regenxbio Stock (Investor's Business Daily)
07:30AM	REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs (PR Newswire)
06:06AM	Regenxbio gene therapy trials suspended by FDA over safety worries (BioPharma Dive)
Jan-26-26 02:49PM	Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope. (Barrons.com)
Jan-19-26 05:20PM	REGENXBIO Inc. (RGNX): A Bull Case Theory (Insider Monkey)
Jan-11-26 03:00PM	REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program (PR Newswire)
Dec-18-25 07:05AM	REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-25-25 07:05AM	REGENXBIO to Participate in Upcoming Investor Conference (PR Newswire) +9.98%
Nov-06-25 02:08PM	Regenxbio Inc (RGNX) Q3 2025 Earnings Call Highlights: Strong Financial Position and Strategic ... (GuruFocus.com)
08:25AM	Regenxbio (RGNX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:25AM	Regenxbio: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights (PR Newswire)
Oct-30-25 07:05AM	REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program (PR Newswire)
Oct-29-25 07:05AM	REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights (PR Newswire)
Oct-15-25 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire) +9.33%
Oct-09-25 07:05AM	REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting (PR Newswire)
Oct-06-25 07:05AM	REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD (PR Newswire)
Sep-29-25 07:05AM	REGENXBIO Announces Presentation at the World Muscle Society (PR Newswire)
Sep-11-25 12:45PM	SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag (Zacks)
Sep-05-25 01:51PM	Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date (Benzinga)
07:05AM	REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE Trial of RGX-121 for Treatment of MPS II (PR Newswire)
Aug-28-25 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-19-25 07:13AM	PTC drug for Friedrichs ataxia rejected; Lilly sells nearly $7B in bonds (BioPharma Dive) -7.81%
Aug-18-25 05:00PM	REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II (PR Newswire)
Aug-12-25 08:50AM	Are Options Traders Betting on a Big Move in Regenxbio Stock? (Zacks) +8.58%
Aug-07-25 08:20AM	Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:18AM	Regenxbio: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights (PR Newswire)
07:00AM	REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy (PR Newswire)
Aug-06-25 06:00PM	Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-31-25 07:05AM	REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights (PR Newswire)
Jul-24-25 08:55AM	REGENXBIO Inc. (RGNX): A Bull Case Theory (Insider Monkey)
Jul-10-25 11:54AM	REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy (PR Newswire)
Jun-20-25 11:27AM	Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street. (Barrons.com)
Jun-19-25 03:00AM	Gene Therapy Has Lost Support on Wall Street. There's Still Hope for Big Cures. (Barrons.com)
Jun-06-25 07:02AM	Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update (BioPharma Dive) +14.95%
Jun-05-25 07:05AM	REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE TRIAL OF RGX-202 (PR Newswire) -17.06%
Jun-02-25 07:05AM	REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE Trial of RGX-202 (PR Newswire) +16.95%
May-20-25 07:00AM	Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff (BioPharma Dive)
May-19-25 04:05PM	REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million (PR Newswire) +10.12%
May-14-25 07:47AM	FDA to review Regenxbio's gene therapy BLA for Hunter syndrome (Pharmaceutical Business Review)
07:13AM	FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment (PR Newswire)
May-13-25 09:44AM	Q1 2025 Regenxbio Inc Earnings Call (Thomson Reuters StreetEvents)
07:05AM	REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II (PR Newswire)
03:09AM	Regenxbio Inc (RGNX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and Financial ... (GuruFocus.com)
May-12-25 05:25PM	Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates (Zacks) +5.98%
04:23PM	Regenxbio: Q1 Earnings Snapshot (Associated Press Finance)

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

PresidentMr. Curran M. Simpson M.S.

J.D.Mr. Patrick J. Christmas II

Executive VP & Chief Medical OfficerDr. Stephen Pakola M.D.

Executive VP & CFOMr. Mitchell Chan M.B.A.

Executive VP of Product Development & CTOMr. Craig Malzahn

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PAKOLA STEVE	Chief Medical Officer	May 11 '26	Sale	11.02	15,309	168,705	232,617	May 13 05:18 PM
STEPHEN PAKOLA	Officer	May 11 '26	Proposed Sale	10.55	34,917	368,374		May 11 04:36 PM
PAKOLA STEVE	Chief Medical Officer	Mar 10 '26	Sale	10.35	5,124	53,033	247,926	Mar 12 06:17 PM
STEPHEN J PAKOLA	Officer	Mar 10 '26	Proposed Sale	10.38	5,124	53,187		Mar 10 04:36 PM
Mills Kenneth T.	Director	Jan 27 '26	Option Exercise	13.09	225,000	2,945,250	707,871	Jan 29 04:58 PM
Simpson Curran	Chief Executive Officer	Oct 09 '25	Sale	12.62	20,811	262,635	216,162	Oct 10 06:38 PM
CURRAN M SIMPSON	Director	Oct 09 '25	Proposed Sale	12.22	20,811	254,310		Oct 09 04:19 PM
Simpson Curran	Chief Executive Officer	Sep 29 '25	Sale	10.03	7,624	76,469	236,973	Oct 01 05:02 PM
Simpson Curran	Chief Executive Officer	Sep 10 '25	Sale	10.02	7,734	77,495	244,597	Sep 12 04:30 PM
CURRAN M SIMPSON	Director	Sep 10 '25	Proposed Sale	9.89	15,358	151,891		Sep 10 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RGNX

Regenxbio Inc

Upgrade your Finviz experience